...
首页> 外文期刊>The journal of clinical investigation >Pathogenic variants in TNNC2 cause congenital myopathy due to an impaired force response to calcium
【24h】

Pathogenic variants in TNNC2 cause congenital myopathy due to an impaired force response to calcium

机译:TNNC2的致病变体由于对钙的力响应受损而导致先天性肌病

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Troponin C (TnC) is a critical regulator of skeletal muscle contraction; it binds Ca~(2+) to activate muscle contraction. Surprisingly, the gene encoding fast skeletal TnC ( TNNC2 ) has not yet been implicated in muscle disease. Here, we report 2 families with pathogenic variants in TNNC2 . Patients present with a distinct, dominantly inherited congenital muscle disease. Molecular dynamics simulations suggested that the pathomechanisms by which the variants cause muscle disease include disruption of the binding sites for Ca~(2+) and for troponin I. In line with these findings, physiological studies in myofibers isolated from patients’ biopsies revealed a markedly reduced force response of the sarcomeres to [Ca~(2+)]. This pathomechanism was further confirmed in experiments in which contractile dysfunction was evoked by replacing TnC in myofibers from healthy control subjects with recombinant, mutant TnC. Conversely, the contractile dysfunction of myofibers from patients was repaired by replacing endogenous, mutant TnC with recombinant, wild-type TnC. Finally, we tested the therapeutic potential of the fast skeletal muscle troponin activator tirasemtiv in patients’ myofibers and showed that the contractile dysfunction was repaired. Thus, our data reveal that pathogenic variants in TNNC2 cause congenital muscle disease, and they provide therapeutic angles to repair muscle contractility.
机译:肌钙蛋白C(TNC)是骨骼肌收缩的关键调节因子;它结合Ca〜(2+)以激活肌肉收缩。令人惊讶的是,编码快速骨骼TNC(TNNC2)的基因尚未涉及肌肉疾病。在这里,我们在TNNC2中向2名致病变体报告2个家庭。患者呈现出明显,占遗传的先天性肌肉疾病。分子动力学模拟表明,变体导致肌肉疾病的土地机制包括破坏Ca〜(2+)的结合位点和对肌钙蛋白I.根据这些发现,从患者的活组织检查中分离的Mydibers中的生理学研究显示出明显减少SARCOMERES对[CA〜(2+)]的力响应。在实验中进一步证实了这种伤害机构,其中通过从具有重组,突变TNC的健康对照受试者替换肌纤维中的TNC引起收缩功能障碍。相反,通过用重组,野生型TNC取代内源性突变TNC来修复来自患者的肌纤维的收缩功能障碍。最后,我们测试了快速骨骼肌肌钙蛋白激活剂Tirasemtiv在患者肌纤维中的治疗潜力,并显示了收缩功能障碍。因此,我们的数据显示TNNC2中的致病变异导致先天性肌肉疾病,它们提供治疗角度以修复肌肉收缩性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号